

1           **Clinical management, epidemiology, and recurrence of human cystic**  
2           **echinococcosis in a secondary care level hospital in an endemic area of the**  
3           **Andes in Sicuani, Cusco, Peru**

4           Roberto Pineda-Reyes<sup>1</sup>, Miguel M. Cabada<sup>2,3</sup>, Bolor Bold<sup>4,5</sup>, Maria L. Morales<sup>2</sup>, Jan  
5           Hattendorf<sup>1</sup>, Paola Vergaray<sup>6</sup>, Ruben Bascope<sup>7</sup>, Jakob Zinsstag<sup>1\*</sup>

6           <sup>1</sup>One Health Group, Human and Animal Health Unit, Department of Epidemiology and  
7           Public Health, Swiss Tropical and Public Health Institute, associated to University of Basel,  
8           Allschwil, Switzerland

9           <sup>2</sup>Cusco Branch – Alexander von Humboldt Tropical Medicine Institute, Universidad Peruana  
10          Cayetano Heredia, Cusco, Peru

11          <sup>3</sup>Division of Infectious Diseases, Department of Internal Medicine, University of Texas  
12          Medical Branch, Galveston, TX, USA

13          <sup>4</sup>School of Global Health, Chinese Centre for Tropical Diseases Research, Shanghai Jiao  
14          Tong University School of Medicine, Shanghai 200025, China

15          <sup>5</sup>National Center for Zoonotic Disease, Ulaanbaatar 18131, Mongolia.

16          <sup>6</sup>Departamento de Cirugia, Hospital Alfredo Callo Rodriguez, Sicuani, Cusco, Peru

17          <sup>7</sup>Programa de Control de Enfermedades Zoonoticas, Gerencia Regional de Salud de Cusco,  
18          Cusco, Peru

19          \* Corresponding author (JZ): E-mail: [jakob.zinsstag@swisstph.ch](mailto:jakob.zinsstag@swisstph.ch) Phone: +41 61 284 81 39

20          *Keywords: recurrence, hydatid disease, echinococcosis, Andes, South America*

21          *Word count: Abstract, 252 words; manuscript text, 3632.*

22          *Running head: Recurrence of cystic echinococcosis in Sicuani, Cusco, Peru*

23          *Tables and figures: 5 tables, 1 figure.*

24 **Abstract**

25 Peru has the highest incidence of human cystic echinococcosis (CE) in South America and  
26 most cases are reported in the Central and Southern Peruvian Andes, including the Cusco  
27 region. We reviewed medical records of patients with CE admitted between 2010-2019 to a  
28 level 2 Hospital in Sicuani, to collect data on the surgical management and disease  
29 recurrence in the Canchis province of Cusco. Records of 115 patients were analyzed in  
30 detail. The median age was 25 years (IQR, 16-46) and 60% were female. Most patients  
31 (68.7%) presented with a single liver cyst. The Gharbi classification was used in 75/107  
32 (70.1%) patients with an ultrasound and 91/142 cysts (64.8%). Thirty one (34.1%) were  
33 classified as Gharbi I, 33 (36.3%) Gharbi II, 21 (23.1%) Gharbi III, and 6 (6.6%) Gharbi IV.  
34 Pre-surgical complications were reported in 41.7%. One hundred two patients underwent  
35 surgery. In 46.1%, one cyst spillage prevention measure was documented, 5.9% had two,  
36 and one had the three recommended measures. Post-surgical cyst recurrence was reported  
37 in 16.5% at a median 32.3 months (IQR, 3.9-46.6) and readmissions in 12.7%. In the  
38 multivariable analysis, having  $\geq 3$  cysts (OR 9.5, 95% CI 1.3-85.5), having two pre-surgical  
39 complications (OR 12.6, 95% CI 1.8-125.6), and receiving pre-surgical albendazole (OR 5.2,  
40 95% CI 1.3-23.9) were associated with cyst recurrence. Advanced and complicated CE  
41 disease and post-surgical recurrence were common in Sicuani. Standardization of  
42 ultrasound staging-guided clinical management along with surgical spillage prevention  
43 measures could effectively decrease the disease burden linked to clinical care, improving  
44 outcomes and decreasing costs.

45

46

47

48

49

## 50 **Introduction**

51 Cystic echinococcosis (CE) is a parasitic zoonosis caused by the metacestode stage of the  
52 dog tapeworm *Echinococcus granulosus* (1). *E. granulosus* has a global distribution, being  
53 endemic in South America, North and East Africa, Central Asia and China (2). Peru has the  
54 highest incidence of CE in South America, accounting for 84.8% of all reported cases in year  
55 2018 (3). The district of Sicuani in the Cusco region is a highly endemic area in the Southern  
56 Peruvian Andes. Up to 45% of CE cases referred to tertiary care hospitals in Cusco are from  
57 Sicuani (4). A population survey in four communities also found the highest prevalence in  
58 Sicuani (5). The economic and urban expansion of the Sicuani city have created areas  
59 where informal livestock slaughter activities, stray dogs, and humans interact closely.  
60 Prompt diagnosis and appropriate treatment of cases in Sicuani are crucial to address the  
61 burden of CE in the healthcare system.

62 The WHO-Informal Working Group on Echinococcosis (WHO-IWGE) ultrasound staging  
63 system is used to diagnose and guide the clinical management of liver CE (6). However,  
64 many low- and middle-income countries (LMIC) have not implemented the proposed WHO  
65 ultrasound staging exposing patients to unnecessary procedures (7). CE is associated with  
66 high post-surgical recurrence risk, with rates that range between 4.7% and 16.4% (8-11).  
67 Clinical characteristics such as the cyst size, number of cysts, and presence of  
68 complications have been associated with disease severity and recurrence (10, 12, 13).  
69 Treatment precautions to avoid cyst rupture and spillage may decrease the risk of  
70 recurrence related to surgical care.

71 The expert consensus on diagnosis and treatment of CE recommends the use of hypertonic  
72 saline-soaked drapes for surgical field protection, injection of a scolicedal agent into the cyst,  
73 and prescription of pre-surgical albendazole (ABZ) to prevent intraabdominal protoscolex  
74 spillage during surgery (6). Increasing evidence shows that appropriate standardization of  
75 surgical procedures may be associated with lower risk of recurrence (14-16). Similarly, the

76 “watch-and-wait” approach for inactive cysts should be the standard of care to spare  
77 asymptomatic patients from unnecessary treatment (17, 18).

78 We conducted a review of medical records of patients hospitalized in the Alfredo Callo  
79 Rodriguez Hospital in Sicuani during a 10-year period to describe the CE management in  
80 Sicuani, determine the post-surgical recurrence rate, and the risk factors for recurrence.

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

## 98 **Methods**

### 99 *Study design and setting*

100 This is a review of medical records from patients hospitalized at the Alfredo Callo Rodriguez  
101 Hospital in Sicuani. This hospital is a level 2 public health center that provides specialty  
102 medical care to patients from the Canchis and Canas provinces of Cusco (19). We collected  
103 data from all patients admitted to the hospital for CE between January 1, 2010 and  
104 December 31, 2019. The pre-COVID-19 period was selected to avoid collecting information  
105 that could reflect gaps in care or practice of CE treatment in Sicuani because of the public  
106 health emergency. This timeframe also coincides with the renovation and expansion of  
107 surgical services in the hospital in 2010.

108 The city of Sicuani is the capital of the Canchis province in the Cusco region at an elevation  
109 of 3,548 meters above sea level. The Sicuani district has an urban population of 47,386 and  
110 a rural population of 10,441 habitants (20). Sicuani is a commerce center for farmers of the  
111 surrounding areas and is the second largest city in the Cusco region.

### 112 *Study procedures*

113 Medical record numbers of patients with CE were identified using ICD-10 codes (B67.0-  
114 B67.9) assigned as the discharge diagnosis through the Hospital's Statistics Department.  
115 Surgical logbooks were handsearched to ensure all surgical CE cases were retrieved.  
116 Demographic and clinical data were collected via ODK software (© 2022 Get ODK Inc.,  
117 California, USA) using an electronic Case Report Form, which was piloted at the start of data  
118 collection to ensure data accuracy.

### 119 *Definitions*

120 The three evaluated *spillage-prevention measures* included the use of drapes soaked on  
121 hypertonic saline for surgical field protection, injection of hypertonic saline into the cyst prior  
122 to evacuation of contents, and the prescription of pre-surgical ABZ (6). *Post-surgical*

123 *recurrence* was defined as the development of a new cyst at or near the site of the  
124 previously removed metacestode and/or within a cavity (e.g., peritoneum, pleura) where  
125 cyst(s) were operated on. The *time-to-recurrence* was estimated as the time from the  
126 surgery date until the date of recurrence diagnosis. In one case the date of recurrence was  
127 recorded as “2024” and it was assigned the first day of this year as the date. *New cyst* was  
128 defined as a newly diagnosed cyst in a location different from other operated cysts.  
129 *Readmission* was defined as return to inpatient care related to CE after discharge.  
130 *Readmission rate* was calculated by dividing the number patients with at least one  
131 readmission by the total number of hospitalization discharges.

### 132 *Cumulative incidence calculation*

133 The annual cumulative incidence of new hospital admissions was calculated dividing the  
134 number of new CE hospitalizations per year by the total population at risk each year. The  
135 population at risk was defined as the total population of the Canas and Canchis provinces  
136 per year. Population data for years 2015 to 2019 was extracted from a repository database  
137 of the Peruvian Ministry of Health and data for years 2009 to 2014 was extracted from CPI  
138 database (21, 22).

### 139 *Statistical analysis*

140 Data analysis and visualization were performed using the R software, version 4.3.2 (R  
141 Foundation for Statistical Computing, Vienna, Austria). Means with standard deviation (SD),  
142 medians with interquartile range (IQR), and frequencies were used to assess the  
143 distributions of demographic, epidemiological, and clinical characteristics of patients. The  
144 association between variables and the outcome ‘post-surgical recurrence’ was assessed  
145 using non-parametric tests such as Chi-Square and Fisher’s exact test. A multivariable  
146 logistic regression analysis was performed to determine independent associations with the  
147 outcome variable. We assessed a pre-defined model with variables of clinical or  
148 epidemiological relevance in unadjusted logistic regression analyses for each variable.

149 These variables included age, sex, duration of symptoms, cyst diameter, number of cysts,  
150 pre-surgical complications, affected liver lobe or segment, spillage prevention measures,  
151 post-surgical ABZ, and post-surgical complications. Variables with significant associations in  
152 the unadjusted models were considered in the multivariable analysis. The multivariable  
153 model was adjusted for age and sex. A *P* value of <0.05 was considered statistically  
154 significant. Confidence intervals were calculated at the 95% level.

155 *Ethical Statement*

156 This study was reviewed and approved by the Ethics Committee of Northern and Central  
157 Switzerland (Ethikkommission Nordwest- und Zentralschweiz, EKNZ) and the Institutional  
158 Ethics Committee (Comite Institucional de Etica en Investigacion) of the Universidad  
159 Peruana Cayetano Heredia in Lima, Peru.

160

161 **Results**

162 *Demographic and clinical characteristics*

163 One hundred and twenty-five medical record numbers were identified. Six were duplicated, 2  
164 were mislabeled as CE, and 2 had missing charts. In total, 115 unique medical records from  
165 patients with CE and clinical information were included in the study (**Table 1**). The median  
166 age was 25 years (IQR, 16-46) and 60% were female. Most patients (103, 89.6%) were  
167 residents of the Canchis province and 73.9% lived in the Sicuani district. Fifty-six patients  
168 (48.7%) were referred from primary healthcare centers, and 57.1% of these were referred  
169 from the Pampaphalla health center.

170 One hundred eighty-five echinococcal cysts were diagnosed in the 115 patients, 169 were  
171 diagnosed upon presentation to the hospital and 16 during readmissions. These involved the  
172 liver, lungs, stomach, spleen, duodenum, gallbladder, diaphragm, adnexa, bladder, and  
173 colon. Most (142, 84%) were located in the liver, 16 within the abdominal cavity, and 11 in  
174 the lungs. Four patients had disseminated liver and intraabdominal cysts. The maximum  
175 number of lung cysts per patient was 2. The median largest diameter for liver cyst was 12.8  
176 cm (IQR, 9.2-15.0) and for lung cysts was 8.5 cm (IQR, 4.5-12.6). Seventy-seven (67%)  
177 patients carried a liver cyst of  $\geq 10$  cm diameter.

178 Most patients (98, 85.2%) presented with only liver cysts, 7 (6.1%) with both liver and  
179 intraabdominal cysts, 5 (4.3%) with liver and lung cysts, and 5 (4.3%) with only lung cysts  
180 (**Table 2**). Most patients presented with a single liver cyst (79, 68.7%). Forty-eight (41.7%)  
181 cases presented with complicated cysts before surgery, 31 (27%) had one pre-surgical  
182 complication, 8 (7%) had two, and 9 (7.8%) had three or more. The most common cyst  
183 complications before surgery were infection of the cyst content (17, 14.9%), cysto-biliary  
184 fistulas (9, 7.8%), liver abscess (9, 7.8%), cyst rupture (8, 7.0%), and peritonitis (5, 4.3%)  
185 (**Table 3**).

186 *Ultrasound diagnosis*



187 One hundred seven patients (93%) had a diagnostic ultrasound. In 75 (70.1%), a liver  
188 ultrasound was performed and used for staging according to the Gharbi classification (6) and  
189 in 20 (18.7%) a liver ultrasound was performed but no staging was reported. Twelve patients  
190 had lung cysts, disseminated disease, complicated cysts, or unclear or missing ultrasound  
191 reports precluding the use of a cyst diagnostic and management classification. In total, 91  
192 (64.8%) of the 142 liver cysts were staged using the Gharbi classification. Thirty-one (34.1%)  
193 were Gharbi I, 33 (36.3%) Gharbi II, 21 (23.1%) Gharbi III, and 6 (6.6%) Gharbi IV. Seven  
194 (6.1%) patients were diagnosed with inactive cysts, including one who had a Gharbi IV cyst  
195 diagnosed intraoperatively. In one of these patients, the cyst was described in the surgical  
196 report as containing multiple daughter cysts (Gharbi III).

197 *Treatment, protoscolex-spillage prevention measures, and post-surgical complications*

198 Only patients with liver and intraabdominal cysts underwent surgery in Sicuani (102, 88.7%).  
199 Ninety five of the 102 patients (93.1%) underwent conventional surgery, 6 (5.9%)  
200 laparoscopic surgery, and one laparoscopic surgery converted to conventional laparotomy.  
201 The most common surgical techniques were cystectomy plus drainage (74, 72.5%) and  
202 pericystectomy plus drainage (9, 8.8%) (**Table 4**). In one case a Gharbi IV cyst was found  
203 and not excised and two patients with inactive cysts (2%) underwent excision. In one case  
204 the liver cyst was not found during the surgery. None of the patients had a percutaneous  
205 procedure performed. In 18 (17.6%) patients, the operative report did not describe the  
206 anatomical location of the liver cyst. Seventy (68.6%) patients had right liver lobe cysts, 26  
207 (25.5%) left liver lobe cysts, and 12 (11.8%) had cysts in both liver lobes. In 46 (45.1%)  
208 patients the liver segment VIII was involved, in 32 (31.4%) the segment VII, in 24 (23.5%)  
209 the VI, in 17 (16.7%) the IV, in 12 (11.8%) the V, in 10 (9.8%) the II, in 8 (7.8%) the III, and in  
210 one patient the segment I.

211 Forty-seven (46.1%) patients had at least one surgical spillage prevention measure  
212 documented, 6 (5.9%) had two, and only one had the three recommended spillage  
213 prevention measures. Pre-surgical ABZ was used in 33 (32.4%) cases, injection of

214 hypertonic saline into the cyst before evacuation of contents was used in 16 (15.7%) cases,  
215 and drapes soaked with hypertonic saline were used for surgical field protection in 6 (5.9%)  
216 cases. Peri-surgical ABZ within 6 hours of surgery was not used in any of the cases (16).

217 ABZ was the only antiparasitic prescribed. In 57 (55.9%) patients, ABZ was prescribed after  
218 surgery, in 27 (26.5%) before and after surgery, in 7 (6.9%) no ABZ was prescribed, in 6  
219 (5.9%) ABZ was prescribed only before surgery, and in 5 cases the timing of the prescription  
220 was unknown. The median post-surgical duration of ABZ treatment prescribed was 30 days  
221 (IQR, 22-34) and the median pre-surgical duration of ABZ treatment prescribed was 2 days  
222 (IQR, 1-4).

223 Post-surgical complications occurred in 22 (21.6%) patients. The most common were the  
224 development of residual fluid collections (14, 13.7%), post-surgical abscess (3, 2.9%), and  
225 biliary leakage (3, 2.9%) (**Table 3**). The three patients with post-surgical liver abscess were  
226 readmitted to the hospital.

#### 227 *Post-surgical recurrence, readmission, and cumulative incidence*

228 One patient required a second surgical intervention within the same hospitalization for post-  
229 surgical biliary leak, and one required intensive care due to post-surgical hemodynamic  
230 instability. Eleven (9.6%) patients were referred to a higher level of care, 9 for treatment of  
231 pulmonary CE, 1 for post-surgical shock, and 1 for potential need of post-surgical intensive  
232 care. Of these, 10 patients went to the Hospital Regional del Cusco and 1 patient to the  
233 Hospital Antonio Lorena in Cusco. Post-surgical recurrence was documented in 16/97  
234 (16.5%) patients. The median time to recurrence after surgery was estimated at 32.3 months  
235 (IQR, 3.9-46.6). The multivariable logistic regression analysis showed that having  $\geq 3$  cysts  
236 compared to 1 cyst (50% vs 15.1%, OR=9.54, 95% CI 1.33-85.47), having two pre-surgical  
237 complications compared to having none (57.1% vs 16.9%, OR=12.62, 95% CI 1.8-125.64),  
238 and receiving a prescription for pre-surgical ABZ compared to not receiving it (27.3% vs

239 10.9%, OR=5.16, 95% CI 1.33-23.93) were associated with post-surgical recurrence (**Figure**  
240 **1**).

241 Fourteen (14/110, 12.7%) patients were readmitted to the Hospital de Sicuani at least once,  
242 6 did for cyst recurrence, 2 for treatment complications, 2 for complications of a previous  
243 cyst plus cyst recurrence, 3 for elective two-stage treatment, and one for a new cyst. One  
244 patient had 2 readmissions. Twelve out of the 14 patients with readmissions had active  
245 echinococcal cysts. The median age was 40 years (IQR, 26.5-62), 7 (58.3%) were female,  
246 and 5 (41.7%) were referred from the Pampaphalla health center. Single liver cyst was the  
247 presentation in 9/12 (75%) of patients with readmissions. Readmissions contributed with 16  
248 additional cysts to the overall count for the 10-year study period. The annual cumulative  
249 incidence of new hospital admissions for CE at the Alfredo Callo Rodriguez Hospital of  
250 Sicuani are reported in **Table 5**.

251

252

253

254

255

256

257

258

259

260

261

262 **Discussion**

263 Our study describes the clinical characteristics and management of CE at a secondary care  
264 level hospital located in an endemic area in the Southern Peruvian Andes. We found that  
265 most CE patients requiring hospital admission in Sicuani were part of the economically  
266 active population and one-third were younger than 18 years. Advanced echinococcal  
267 disease was common, with nearly 70% of patients having liver cysts  $\geq 10$  cm in diameter and  
268 42% presenting with pre-surgical complications. Despite the use of ultrasound in the  
269 evaluation of CE in 90% of the cases, the WHO-IWGE system for diagnosis and  
270 management of liver CE was not used in any of the patients. Instead, the Gharbi  
271 classification was used on a limited number of cysts. Spillage prevention measures were  
272 documented in less than half of the surgical procedures performed. One in six patients had  
273 recurrence of CE after surgery and one in eight patients was readmitted to the hospital at  
274 least once. Our data suggest that educational interventions could improve the medical and  
275 surgical management of CE in Hospital Sicuani and decrease the morbidity associated with  
276 disease recurrence and surgical procedures.

277 The Alfredo Callo Rodriguez Hospital of Sicuani serves as a referral center to the Canas and  
278 Canchis provinces. These provinces have a large young age populations being prominently  
279 affected by CE. The latent period of CE, between infection and clinical presentation, typically  
280 lasts many years suggesting that active transmission occurs in Sicuani and that it occurs  
281 early in life. A large case series of hospitalized patients in the Extremadura and Castilla-  
282 Leon regions of Spain showed a distribution skewed towards the older age groups with only  
283 2% cases presenting in patients younger than 19 years (23, 24). The authors attributed this  
284 age distribution in part to the successful interruption of CE transmission by control programs.  
285 A similar scenario was described in Chile, where most reported cases between 2018-2022  
286 were diagnosed among patients 45 to 74 years (25). Efforts to control CE transmission in the  
287 Canas and Canchis provinces were limited to the treatment of dogs in rural areas and

288 sporadic screening of children. A concerted effort with a One Health approach is needed to  
289 formulate control strategies in the area.

290 Most of the patients in our study had liver cysts and 41.7% presented with complications.  
291 This proportion of complications is comparable with a study in Salamanca, Spain (40.3%)  
292 but higher than other case series (4%) (26, 27). Collado-Aliaga and colleagues (26) found in  
293 a tertiary care hospital a bigger proportion of mechanical complications (25% vs 20%),  
294 including biliary fistulas (13.4% vs 7.8%) and mass effect (5.5% vs 4.4%). We observed a  
295 larger proportion of infectious complications (25.2% vs 17.8%), cyst rupture (8.7% vs 2.9%),  
296 and cysts >10 cm in diameter (68.7% vs 45% >7 cm). These differences could be due to  
297 selection bias from hospital level of care or complexity of the clinical care (secondary vs  
298 tertiary care), and differences in healthcare access.

299 Having two pre-surgical complications was associated with increased odds of post-surgical  
300 recurrence compared to not having complications. Single complications including cyst  
301 rupture and fistulas did not have an association with recurrence. Other studies were also  
302 unable to demonstrate associations of infectious, mechanical or allergic complications and  
303 recurrence (9, 26). In one of these studies, 64% patients were asymptomatic at the moment  
304 of diagnosis, which could indicate that the risk of recurrence depends on more than one  
305 clinical variable but on surgical technique performance and post-surgical care (9). Larger  
306 cyst diameter has been proposed as a marker of disease severity and a risk factor for  
307 recurrence (12). We did not find an association between cyst diameter and pre-surgical  
308 complications, recurrence, or readmission. Although other studies reported cysts with  
309 smaller sizes (median 6.6 cm and 10 cm vs 13 cm in our cohort), these could not  
310 demonstrate an associations with complications or recurrence either (11, 13, 26). We did  
311 observe an independent association between increasing number of cysts and the risk of  
312 post-surgical recurrence in our patients. Number of cysts has been previously identified as a  
313 risk factor for complications and recurrence. For example, Pacifico and colleagues detected  
314 four-times increased risk for recurrence among those with  $\geq 3$  cysts, and another study also

315 found having  $\geq 3$  cysts was an independent risk factor for recurrence (10, 13). This could be  
316 the result of large parasitic burden secondary to repeated cycles of infection or subclinical  
317 cyst rupture and seeding long prior to hospital admission.

318 Documentation of adequate ultrasound staging was observed in 91 out 142 diagnosed liver  
319 cysts. Ultrasound diagnosis is not yet fully implemented in LMIC (7). In none of the cases  
320 reviewed in this study the WHO-IWGE staging system was used. The WHO-IWGE  
321 classification serves as a guide for the clinical management to either medical, percutaneous,  
322 surgical or 'watch and wait' approach (6). Thirty-six (35.3%) patients who underwent surgery  
323 in our study presented without complications and had Gharbi I or II liver cysts, being in 5  
324 cases between 5-10 cm in diameter and in 30 cases  $\geq 10$  cm. Some of these patients could  
325 have been candidates for percutaneous treatment (28); however, this treatment option is still  
326 not widely available in Peru. Patients with Gharbi III cysts in our study had a greater  
327 proportion of post-surgical recurrence (29.4%) compared to the other stages (10.7% of  
328 Gharbi I, 7.7% of Gharbi II, and 0% of Gharbi IV). Surgery is the treatment of choice for  
329 Gharbi III cysts due to the high recurrence rates reported in percutaneous treatment studies  
330 (28, 29). Proposed explanations for these findings include multiple daughter cysts within a  
331 solid matrix being more difficult to access and drain, as well as the presence of undetected  
332 very small daughter cysts that could not have enough exposure to the scolicial agent or  
333 were not properly drained (29, 30). Moreover, two patients in our study had inactive cysts  
334 excised and one patient was referred to Cusco Regional Hospital for management of a  
335 Gharbi IV cyst. Ultrasound screening for early diagnosis along with standardization of WHO-  
336 IWGE staging and implementation of percutaneous invasive procedures may improve CE  
337 outcomes in Sicuani, decreasing costs, unnecessary procedures and hospitalization time.

338 We found a higher post-surgical recurrence rate in comparison with other studies evaluating  
339 this measure (8, 10, 11, 31). This is particularly concerning, when only a minority of patients  
340 had documentation of the recommended surgical spillage prevention measures. In some  
341 cases, it was described that surgical field drapes were soaked on normal saline or iodine

342 rather than hypertonic saline and the instillation of a scolicial agent into the cyst cavity was  
343 performed after the cyst opening and evacuation of contents. Although we did not find a  
344 protective association between these measures and recurrence, proper standardization has  
345 been associated with null recurrence at 24 months in prospective studies (16). Furthermore,  
346 pre-surgical ABZ had a paradoxically positive association with recurrence in our cohort. This  
347 phenomenon was observed in other study in which patients receiving antiparasitics were  
348 associated with higher risk of recurrence (9). This could be the result of an indication bias in  
349 a retrospective study, in which the more complicated patients were treated more carefully  
350 and documentation was more precise. Pre-surgical ABZ remains a core measure of  
351 protoscolex spillage-prevention in liver CE (28). Prospective studies carefully assessing the  
352 appropriate timing and dosing of antiparasitics will help elucidate this clinical gap to improve  
353 outcomes.

354 Our study had limitations that should be acknowledged. First, this is a retrospective review of  
355 paper-form medical charts with a small sample size. Missing information in certain variables  
356 such as ultrasound staging did not allow testing their association with our outcome. Second,  
357 as the Hospital Archives Department had a digitalized database of medical record numbers  
358 since 2017, cases of years 2010-2016 had to be handsearched in the surgical logbooks.  
359 Therefore, patients who were hospitalized during this period and did not have surgery are  
360 missing in our cohort. Third, the description of symptoms, complications, and management  
361 of patients in our study represent the judgement of practicing clinicians in Sicuani during a  
362 large time span. These may not concur with the standard of care in other contexts and  
363 generalizations should be carefully assessed. Finally, the lack of follow up in some patients  
364 may have underestimated our recurrence outcome.

365 In conclusion, advanced and complicated liver CE and post-surgical recurrence were  
366 common among hospitalized patients in Sicuani, Cusco, Peru. Practical measures including  
367 standardization of ultrasound staging-guided clinical management, protoscolex spillage-

368 prevention measures, and follow-up could effectively decrease the burden linked to clinical  
369 care, improving outcomes and decreasing costs in Sicuani.

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388



## 389 **Acknowledgements**

390 We thank the Alfredo Callo Rodriguez Hospital's Administration Office as well as the  
391 personnel of the Statistics and Archives Department for their assistance during the study  
392 period.

393

## 394 **Financial support**

395 This study was supported by the "Bologna Master Thesis" funding from the Department of  
396 Education of the University of Basel, Switzerland.

397

## 398 **Conflicts of interest**

399 The authors have no competing interests.

400

## 401 **Authors' details**

402 **RP-R:** Swiss Tropical and Public Health Institute, associated to University of Basel,  
403 Allschwil, Switzerland, Kreuzstrasse 2, 4123 Allschwil, Switzerland, [repineda1@gmail.com](mailto:repineda1@gmail.com);  
404 **MMC:** Cusco Branch – Alexander von Humboldt Tropical Medicine Institute, Universidad  
405 Peruana Cayetano Heredia and Infectious Disease Division, University of Texas Medical  
406 Branch, Galveston Texas, 301 University Boulevard, Rte. 0435, Galveston, TX 77555-0435,  
407 USA, [micabada@utmb.edu](mailto:micabada@utmb.edu); **BB:** School of Global Health, Chinese Centre for Tropical  
408 Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai 200025,  
409 China and National Center for Zoonotic Disease, Ulaanbaatar 18131, Mongolia,  
410 [bolor.bold.ch@gmail.com](mailto:bolor.bold.ch@gmail.com); **MLM:** Cusco Branch – Alexander von Humboldt Tropical  
411 Medicine Institute, Universidad Peruana Cayetano Heredia, Jr. Jose Carlos Mariategui J6  
412 Urb. Santa Monica, Distrito Wanchaq 08002, Cusco, Peru, [maria.morales.f@upch.pe](mailto:maria.morales.f@upch.pe); **JH:**  
413 Swiss Tropical and Public Health Institute, associated to University of Basel, Allschwil,  
414 Switzerland, Kreuzstrasse 2, 4123 Allschwil, Switzerland, [jan.hattendorf@swisstph.ch](mailto:jan.hattendorf@swisstph.ch); **PV:**  
415 Departamento de Cirugia, Hospital Alfredo Callo Rodriguez – Sicuani, Av. Manuel Callo  
416 Zevallos Nro. 519, Sicuani, Cusco, Peru, [miqxonc21@gmail.com](mailto:miqxonc21@gmail.com); **RB:** Programa de Control  
417 de Enfermedades Zoonoticas, Gerencia Regional de Salud de Cusco, Prolongacion de la  
418 Cultura 1525, Cusco 08003, Peru, [bascopecusco@gmail.com](mailto:bascopecusco@gmail.com); **JZ:** Swiss Tropical and  
419 Public Health Institute, associated to University of Basel, Allschwil, Switzerland,  
420 Kreuzstrasse 2, 4123 Allschwil, Switzerland, [jakob.zinsstag@swisstph.ch](mailto:jakob.zinsstag@swisstph.ch).

421 **References**

- 422 1. Craig PS, McManus DP, Lightowlers MW, Chabalgoity JA, Garcia HH, Gavidia CM,  
423 et al. Prevention and control of cystic echinococcosis. *Lancet Infect Dis.* 2007;7(6):385-94.
- 424 2. Deplazes P, Rinaldi L, Alvarez Rojas CA, Torgerson PR, Harandi MF, Romig T, et al.  
425 Global Distribution of Alveolar and Cystic Echinococcosis. *Adv Parasitol.* 2017;95:315-493.
- 426 3. PAHO/WHO. Equinococosis: informe epidemiológico en la región de América del Sur  
427 - 2018, n.4, 2020: Veterinary Public Health - PANAFTOSA - PAHO/WHO; 2020 [Available  
428 from: <https://iris.paho.org/handle/10665.2/51942>.
- 429 4. Flores Quispe O. Equinococosis quística en niños y adolescentes en los hospitales  
430 Regional del Cusco y Adolfo Guevara Velasco, Cusco a 3400 msnm, 2010-2014. Cusco,  
431 Peru.: San Antonio Abad del Cusco.; 2015.
- 432 5. Tamarozzi F, Hou A, Morales ML, Giordani MT, Vilca F, Mozo K, et al. Prevalence  
433 and Risk Factors for Human Cystic Echinococcosis in the Cusco Region of the Peruvian  
434 Highlands Diagnosed Using Focused Abdominal Ultrasound. *Am J Trop Med Hyg.*  
435 2017;96(6):1472-7.
- 436 6. Brunetti E, Kern P, Vuitton DA, Writing Panel for the W-I. Expert consensus for the  
437 diagnosis and treatment of cystic and alveolar echinococcosis in humans. *Acta Trop.*  
438 2010;114(1):1-16.
- 439 7. Bold B, Hattendorf J, Shagj A, Tserendovdon B, Ayushkhuu T, Luvsandorj A, et al.  
440 Patients with cystic echinococcosis in the three national referral centers of Mongolia: A  
441 model for CE management assessment. *PLoS Negl Trop Dis.* 2018;12(8):e0006686.
- 442 8. Kapan M, Kapan S, Goksoy E, Perek S, Kol E. Postoperative recurrence in hepatic  
443 hydatid disease. *J Gastrointest Surg.* 2006;10(5):734-9.
- 444 9. Velasco-Tirado V, Romero-Alegría Á, Belhassen-García M, Alonso-Sardón M,  
445 Esteban-Velasco C, López-Bernús A, et al. Recurrence of cystic echinococcosis in an  
446 endemic area: a retrospective study. *BMC Infect Dis.* 2017;17(1):455.

- 447 10. El Malki HO, El Mejdoubi Y, Souadka A, Zakri B, Mohsine R, Ifrine L, et al. Does  
448 primary surgical management of liver hydatid cyst influence recurrence? *J Gastrointest Surg.*  
449 2010;14(7):1121-7.
- 450 11. Yosra K, Ghada H, Bochra A, Fatma T, Said J, Riadh J. Predictive Factors of Liver  
451 Hydatid Cyst Recurrence in Children. *J Pediatr Surg.* 2023;58(12):2362-7.
- 452 12. Bedioui H, Ayari H, Bouslama K, Maghrebi H, Hsairi H, Jouini M, et al. [Recurrence of  
453 hydatid cyst of liver: predictive factors: Tunisian experience]. *Bull Soc Pathol Exot.*  
454 2012;105(4):265-9.
- 455 13. Pacifico J, Cabrera R, Salgado-Diaz S, Mormontoy W, Suarez-Ognio L. Factors  
456 associated with pre-surgical complications in patients with cystic echinococcosis from  
457 endemic areas of Peru. *Rev Peru Med Exp Salud Publica.* 2021;38(1):33-40.
- 458 14. Al-Saeedi M, Ramouz A, Khajeh E, El Rafidi A, Ghamarnejad O, Shafiei S, et al.  
459 Endocystectomy as a conservative surgical treatment for hepatic cystic echinococcosis: A  
460 systematic review with single-arm meta-analysis. *PLoS Negl Trop Dis.*  
461 2021;15(5):e0009365.
- 462 15. Abbasi Dezfouli S, El Rafidi A, Aminizadeh E, Ramouz A, Al-Saeedi M, Khajeh E, et  
463 al. Risk factors and management of biliary leakage after Endocystectomy for hepatic cystic  
464 echinococcosis. *PLoS Negl Trop Dis.* 2023;17(10):e0011724.
- 465 16. Al-Saeedi M, Khajeh E, Hoffmann K, Ghamarnejad O, Stojkovic M, Weber TF, et al.  
466 Standardized endocystectomy technique for surgical treatment of uncomplicated hepatic  
467 cystic echinococcosis. *PLoS Negl Trop Dis.* 2019;13(6):e0007516.
- 468 17. Lissandrin R, Tamarozzi F, Mariconti M, Manciuilli T, Brunetti E, Vola A. Watch and  
469 Wait Approach for Inactive Echinococcal Cyst of the Liver: An Update. *Am J Trop Med Hyg.*  
470 2018;99(2):375-9.
- 471 18. Junghanss T, da Silva AM, Horton J, Chiodini PL, Brunetti E. Clinical management of  
472 cystic echinococcosis: state of the art, problems, and perspectives. *Am J Trop Med Hyg.*  
473 2008;79(3):301-11.

- 474 19. Gerencia Regional de Salud Cusco. Analisis de Situacion de Salud - Canchis Cusco,  
475 Peru: Red Nacional de Epidemiologia - RENACE Peru; 2020 [Available from:  
476 [https://www.redsaludcce.gob.pe/Modernidad/archivos/epidemiologia/ASIS/ASIS\\_Canchis\\_2](https://www.redsaludcce.gob.pe/Modernidad/archivos/epidemiologia/ASIS/ASIS_Canchis_2020.pdf)  
477 [020.pdf](https://www.redsaludcce.gob.pe/Modernidad/archivos/epidemiologia/ASIS/ASIS_Canchis_2020.pdf).
- 478 20. Instituto Nacional de Estadistica e Informatica (INEI). Censo 2018, Resultados  
479 Definitivos, Region Cusco. Lima, Peru: Gobierno del Peru; 2018.
- 480 21. Ministerio de Salud del Peru. Estadistica Poblacional Lima: Ministerio de Salud del  
481 Peru.; 2023 [Available from: [https://www.minsa.gob.pe/reunis/data/poblacion\\_estimada.asp](https://www.minsa.gob.pe/reunis/data/poblacion_estimada.asp).
- 482 22. Compania Peruana de Estudios de Mercado y Opinion Publica (CPI Peru).  
483 Estadisticas Poblacionales Peru: CPI Peru; [Available from:  
484 <https://cpi.pe/banco/estadisticas-poblacionales.html>.
- 485 23. Lopez-Bernus A, Belhassen-Garcia M, Prieto-Vicente AJ, Alonso-Sardon M, Carpio-  
486 Perez A, Velasco-Tirado V, et al. [Epidemiological update of hydatid disease in hospitals in  
487 the public health system of Extremadura (2003-2012)]. *Enferm Infecc Microbiol Clin*.  
488 2016;34(4):232-6.
- 489 24. Lopez-Bernus A, Belhassen-Garcia M, Alonso-Sardon M, Carpio-Perez A, Velasco-  
490 Tirado V, Romero-Alegria A, et al. Surveillance of Human Echinococcosis in Castilla-Leon  
491 (Spain) between 2000-2012. *PLoS Negl Trop Dis*. 2015;9(10):e0004154.
- 492 25. Ministerio de Salud - Gobierno de Chile. Informe: Situación de la Equinococosis  
493 Quística/Hidatidosis en Chile, 2018-2022. Chile: Ministerio de Salud - Gobierno de Chile;  
494 2023 [Available from: [https://diprece.minsal.cl/wp-content/uploads/2024/03/INFORME-](https://diprece.minsal.cl/wp-content/uploads/2024/03/INFORME-HIDATIDOSIS-2018-2022.pdf)  
495 [HIDATIDOSIS-2018-2022.pdf](https://diprece.minsal.cl/wp-content/uploads/2024/03/INFORME-HIDATIDOSIS-2018-2022.pdf).
- 496 26. Collado-Aliaga J, Romero-Alegria A, Alonso-Sardon M, Muro A, Lopez-Bernus A,  
497 Velasco-Tirado V, et al. Complications Associated with Initial Clinical Presentation of Cystic  
498 Echinococcosis: A 20-year Cohort Analysis. *Am J Trop Med Hyg*. 2019;101(3):628-35.
- 499 27. Salgado Díaz S, Suarez-Ognio L, Cabrera R. Características clínicas y  
500 epidemiológicas de la equinococosis quística registradas en un área endémica en los Andes  
501 centrales del Perú. *Neotropical Helminthology*. 2007;1(2):69-83.

- 502 28. Kuehn R, Uchiumi LJ, Tamarozzi F. Treatment of uncomplicated hepatic cystic  
503 echinococcosis (hydatid disease). *Cochrane Database Syst Rev.* 2024;7(7):CD015573.
- 504 29. Kabaalioglu A, Ceken K, Alimoglu E, Apaydin A. Percutaneous imaging-guided  
505 treatment of hydatid liver cysts: do long-term results make it a first choice? *Eur J Radiol.*  
506 2006;59(1):65-73.
- 507 30. Men S, Hekimoglu B, Yucesoy C, Arda IS, Baran I. Percutaneous treatment of  
508 hepatic hydatid cysts: an alternative to surgery. *AJR Am J Roentgenol.* 1999;172(1):83-9.
- 509 31. Velasco-Tirado V, Romero-Alegria A, Belhassen-Garcia M, Alonso-Sardon M,  
510 Esteban-Velasco C, Lopez-Bernus A, et al. Recurrence of cystic echinococcosis in an  
511 endemic area: a retrospective study. *BMC Infect Dis.* 2017;17(1):455.

512

513

514

515

516

517

518

519

520

521

522

523

524

525 **Table 1.** General characteristics of 115 patients hospitalized for cystic echinococcosis during the  
 526 period 2010 to 2019 at the Alfredo Callo Rodriguez Hospital of Sicuani, Cusco, Peru.  
 527

Variable* – no. (%)	All patients (n=115)	Pre-surgical complications <sup>a</sup>	
		No (n=63)	Yes (n=48)
Age group			
<18 years	34 (29.6)	18 (28.6)	15 (31.3)
18-64 years	67 (58.3)	41 (65.1)	25 (52.1)
≥65 years	14 (12.2)	4 (6.3)	8 (16.7)
Female	69 (60.0)	35 (55.6)	31 (64.6)
District of residence			
Sicuani	85 (73.9)	47 (74.6)	38 (79.2)
Marangani	7 (6.1)	6 (9.5)	1 (2.1)
Other	18 (15.7)	10 (15.9)	8 (16.7)
Referred from primary care center	56 (48.7)	38 (60.3)	18 (37.5)
Location of cyst			
Only liver	98 (85.2)	57 (90.5)	38 (79.2)
Liver and other intraabdominal	7 (6.1)	4 (6.3)	2 (4.2)
Only lung	5 (4.4)	1 (1.6)	4 (8.3)
Liver and lung	5 (4.4)	1 (1.6)	4 (8.3)
Number of cysts			
Single cyst	84 (73.0)	49 (77.8)	33 (68.8)
2 cysts	20 (17.4)	9 (14.3)	9 (18.8)
≥3 cysts	11 (9.6)	5 (7.9)	6 (12.5)
Largest cyst diameter			
<5 cm	3 (2.6)	1 (1.6)	2 (4.2)
5-10 cm	28 (24.3)	16 (25.4)	12 (25)
≥10 cm	79 (68.7)	45 (71.4)	31 (64.6)
Anemia severity			
No anemia	57 (49.6)	33 (52.4)	24 (50.0)
Mild	27 (23.5)	19 (30.2)	8 (16.7)
Moderate	22 (19.1)	10 (15.9)	12 (25.0)
Severe	3 (2.6)	0 (0.0)	3 (6.3)
Ultrasound performed	107 (93.0)	62 (98.4)	45 (93.8)
Ultrasound staging			
Gharbi staging	75 (65.2)	48 (76.2)	27 (56.3)
No staging method	20 (17.4)	8 (12.7)	12 (25.0)
Other	12 (10.4)	6 (9.5)	6 (12.5)
Treatment approach			
Surgery + post-ABZ	57 (49.6)	37 (58.7)	20 (41.7)
Surgery + pre- & post-ABZ	27 (23.5)	15 (23.8)	12 (25.0)
No treatment	10 (8.7)	2 (3.2)	8 (16.7)
Only surgery	7 (6.1)	4 (6.3)	3 (6.3)
Surgery + pre-ABZ	6 (5.2)	3 (4.8)	3 (6.3)
Only ABZ	3 (2.6)	2 (3.2)	1 (2.1)
Post-surgical complications	22 (19.1)	12 (19.0)	10 (20.8)
Referred to higher care center	11 (9.6)	2 (3.2)	9 (18.8)
Post-surgical recurrence	16 (16.5) <sup>b</sup>	8 (12.7)	6 (12.5)
Readmission	14 (12.7) <sup>c</sup>	9 (14.3)	5 (10.4)

528 \* Non-available data in variables “sex” (n=1), “district of residence” (n=5), “largest cyst diameter”  
 529 (n=5), duration of symptoms (n=12), length of stay (n=5), anemia severity (n=6).

530 <sup>a</sup> Non-available data in 4 patients. ABZ, albendazole, *pre-*, pre-surgical, *post-*, post-surgical.

531 <sup>b</sup> 16/97 surgically treated patients with complete charts.

532 <sup>c</sup> 14/110 discharged patients with complete charts.

534 **Table 2.** Clinical presentation characteristics by anatomical location of cysts.  
535

Variable*	Only liver (n=98)	Liver and other intraabdominal (n=7)	Liver and lung (n=5)	Only lung (n=5)
Median age (IQR)	28 (17-47.5)	21 (13-41)	18 (6-80)	18 (8-23)
Female – no. (%)	57 (58.2)	3 (42.9)	5 (100.0)	4 (80.0)
Symptoms – no. (%)				
Abdominal pain	94 (95.9)	6 (85.7)	2 (40.0)	0 (0.0)
Nausea	26 (26.5)	2 (28.6)	0 (0.0)	0 (0.0)
Vomiting	22 (22.4)	1 (14.3)	0 (0.0)	0 (0.0)
Abdominal mass	6 (6.1)	0 (0.0)	0 (0.0)	0 (0.0)
Fever	5 (5.1)	0 (0.0)	1 (20.0)	3 (60.0)
Shortness of breath	2 (2.0)	0 (0.0)	3 (60.0)	4 (80.0)
Cough	0 (0.0)	0 (0.0)	4 (80.0)	5 (100.0)
Hemoptysis	0 (0.0)	0 (0.0)	1 (20.0)	1 (20.0)
Vomica	0 (0.0)	0 (0.0)	1 (20.0)	1 (20.0)
Median duration of symptoms (IQR)	31 (8-92)	19.5 (14.3-120.8)	13 (7-15)	20 (8-62)
Number of cysts – no. (%)				
Single cyst	79 (80.6)	0 (0.0)	0 (0.0)	5 (100.0)
2 cysts	16 (16.3)	1 (14.3)	3 (60.0)	0 (0.0)
≥3 cysts	3 (3.1)	6 (85.7)	2 (40.0)	0 (0.0)
Median largest cyst diameter (IQR)	13 (9.6-15.1)	9.5 (7.4-13.1)	10.9 (10.7-12)	5 (4-9.8)
Median unadjusted hemoglobin (g/dl) (IQR)	15 (13.5-16.3)	15.1 (14.7-15.5)	13 (12.6-13.5)	13.6 (12-13.6)
Anemia severity – no. (%)				
No anemia	49 (50.0)	5 (71.4)	1 (20.0)	2 (40.0)
Mild	23 (23.5)	1 (14.3)	2 (40.0)	1 (20.0)
Moderate	19 (19.4)	0 (0.0)	2 (40.0)	1 (20.0)
Severe	2 (2.0)	0 (0.0)	0 (0.0)	1 (20.0)
Median WBC count (×10 <sup>9</sup> /L) (IQR)	9.2 (7.5-12.3)	10.3 (8.5-14.4)	11.5 (7.6-12.1)	10.2 (8.0-11.0)
Median eosinophil count (cells/μL) (IQR)	128 (0-300)	352 (176-548)	0 (0-470)	35 (0-81.6)
Median platelet count (×10 <sup>9</sup> /L) (IQR)	315.2 (298.4-350.7)	389 (340-392)	337 (260-378)	492 (357-550)
Median AST (units/L) (IQR)	10.1 (7-18.8)	9 (8-9.5)	39 (22-40.5)	NA
Median ALT (units/L) (IQR)	12 (9-17.7)	11 (9.5-11)	36 (22.5-46.5)	NA
Median total bilirubin (mg/dL) (IQR)	1.02 (0.84-1.39)	0.89 (0.86-1.02)	0.24 (0.18-0.31)	NA
Post-surgical recurrence – no. (%)	13 (13.3)	3 (42.9)	0 (0.0)	0 (0.0)
Readmission – no. (%)	12 (12.2)	2 (28.6)	0 (0.0)	0 (0.0)

536 \* Non-available data in variables “sex” (n=1), “duration of symptoms” (n=12), “largest cyst  
537 diameter” (n=5), “pre-surgical complications” (n=4), “hemoglobin” (n=6), “anemia severity”  
538 (n=6), “WBC count” (n=7), “eosinophil count” (n=28), “platelet count” (n=18), “AST” (n=63),  
539 “ALT” (n=63), “total bilirubin” (n=59), “post-surgical recurrence” (n=5), and “readmission”  
540 (n=5).

541 ALT, alanine transaminase, AST, aspartate transaminase, IQR, interquartile range, WBC,  
542 white blood cell.

543 **Table 3.** Pre-surgical, intraoperative, and post-surgical complications by anatomical  
544 location of cysts.  
545

<b>Complication type*</b>	<b>n=115 (%)</b>
<b>Pre-surgical (n=48, 41.7%)</b>	
Infectious (n=29, 25.2%)	
Purulent cyst fluid	17 (14.8)
Abscess	9 (7.8)
Peritonitis	5 (4.4)
Pneumonia	5 (4.4)
Cholecystitis	2 (1.7)
Cholangitis	1 (0.9)
Mechanical (n=23, 20%)	
Fistula	11 (9.6)
Cysto-biliary	9 (7.8)
Cysto-pleural-bronchial	1 (0.9)
Cholecysto-gastric	1 (0.9)
Cyst rupture or vomica	10 (8.7)
Mass effect	5 (4.4)
Respiratory (n=5, 4.4%)	
Respiratory insufficiency	5 (4.4)
Hemorrhagic (n=3, 2.6%)	
Hemoptysis	2 (1.7)
Hemorrhagic cyst fluid	1 (0.9)
Allergic (n=3, 2.6%)	
Rash/urticaria	3 (2.6)
Other (n=3, 2.6%)	
Abdominal trauma	1 (0.9)
Ectopic pregnancy	1 (0.9)
Pregnancy	1 (0.9)
<b>Intraoperative (n=2, 1.7%)</b>	
Anaphylactic shock	1 (0.9)
Cardiac arrest	1 (0.9)
Hemoperitoneum	1 (0.9)
Spleen laceration	1 (0.9)
<b>Post-surgical (n=22, 19.1%)</b>	
Residual collection	14 (12.2)
Abscess	3 (2.6)
Biliary leakage	3 (2.6)
Cutaneous fistula	2 (1.7)
Adherences	1 (0.9)
Hemorrhage	1 (0.9)
Post-cardiac arrest	1 (0.9)
Sepsis	1 (0.9)
Wound infection	1 (0.9)

\*Patients may have more than one complication.

546  
547  
548  
549  
550  
551



552 **Table 4.** Surgical techniques performed among 102 patients during the study period. In one  
553 case the liver cyst could not be found and the patient was discharged on albendazole.

554  
555

Surgical technique	Patients (n=102)
Cystectomy plus drainage	74 (72.5)
Pericystectomy plus drainage	9 (8.8)
Cystectomy	5 (4.9)
Pericystectomy	4 (3.9)
Laparoscopic cystectomy plus drainage	3 (2.9)
Partial cystectomy plus drainage	2 (2.0)
Enucleation and cystectomy	1 (1.0)
Laparoscopic cystectomy	1 (1.0)
Laparoscopic drainage of abscessed cyst	1 (1.0)

556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573

**Table 5.** Annual cumulative incidence of new hospital admissions for human cystic echinococcosis at the Alfredo Callo Rodriguez Hospital of Sicuani during the period 2010-2019.

Year	New hospital admissions for CE			All hospital admissions, including readmissions			Population at risk <sup>§</sup>	Cumulative incidence ×100,000
	Patients	Echinococcal cysts		Admissions	Echinococcal cysts			
	n=115 (%)	n=169 (%)	Mean cysts per patient (SD)	n=126 (%)	n=185 (%)	Mean cysts per patient (SD)		
2019	21 (18.3)	33 (19.5)	1.57 (1.12)	22 (17.5)	35 (18.9)	1.59 (1.10)	144,607	14.5
2018	16 (13.9)	21 (12.4)	1.31 (0.79)	17 (13.5)	22 (11.9)	1.29 (0.77)	143,826	11.1
2017	16 (13.9)	27 (16.0)	1.69 (1.78)	19 (15.1)	30 (16.2)	1.58 (1.64)	143,059	11.2
2016	12 (10.4)	17 (10.1)	1.42 (1.17)	15 (11.9)	20 (10.8)	1.33 (1.05)	142,266	8.4
2015	20 (17.4)	31 (18.3)	1.55 (0.83)	23 (18.2)	38 (20.5)	1.65 (1.07)	141,444	14.1
2014	9 (7.8)	11 (6.5)	1.22 (0.44)	9 (7.1)	11 (6.0)	1.22 (0.44)	141,900	6.3
2013	5 (4.4)	9 (5.3)	1.8 (0.84)	5 (4.0)	9 (4.9)	1.8 (0.84)	142,300	3.5
2012	9 (7.8)	11 (6.5)	1.22 (0.44)	9 (7.1)	11 (6.0)	1.22 (0.44)	142,800	6.3
2011	5 (4.4)	7 (4.1)	1.4 (0.89)	5 (4.0)	7 (3.8)	1.4 (0.89)	143,200	3.5
2010	2 (1.7)	2 (1.2)	1.0 (0.00)	2 (1.6)	2 (1.1)	1.0 (0.00)	143,600	1.4

\* Not counting one patient readmitted in 2020 for a liver cyst, one patient readmitted in 2020 for multiple liver and intraabdominal cysts, and two patients readmitted for drainage of post-surgical liver abscesses.

§ Combining the Canas and Canchis provinces total population.

CE, cystic echinococcosis, SD, standard deviation.

**Figure 1.** Forest plot exhibiting the multivariable logistic regression analysis for post-surgical recurrence. The left column shows the explanatory variables. Odds ratios and confidence intervals in black represent unadjusted logistic regression models for each independent variable. Odds ratios and confidence intervals in blue represent the multivariable analysis.

ABZ, albendazole, *CI*, confidence interval, *OR*, odds ratio.

